---
title: November 2025 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)
description: A 17-page Quarterly Update has been published on biotechnology company GeoVax, Labs, Inc. (GOVX-NASDAQ).
---

[Crystal Research Associates' Blog ](https://www.crystalra.com/blog)

# [November 2025 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)](https://www.crystalra.com/blog/november-2025-update-on-geovax-labs-inc.-govx-nasdaq)

 Written by [Karen Goldfarb](https://www.crystalra.com/blog/author/karen-goldfarb) | November 17, 2025 at 5:46 PM

Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

**Snapshot of GeoVax**

<https://www.crystalra.com/hubfs/GOVX_Update_11-17-25.pdf>

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing multi-antigen vaccines for infectious diseases and gene-directed therapies for solid tumors. Its lead program, GEO-CM04S1, is an MVA-based COVID-19 vaccine designed to provide broader, more durable protection, particularly for immunocompromised patients who remain underserved by current mRNA vaccines. GEO-CM04S1 is in multiple Phase 2 trials as a primary vaccine in immunocompromised patients (including those with hematologic malignancies or post-transplant status) and as a booster in both patients with chronic lymphocytic leukemia (CLL) and healthy adults previously vaccinated with mRNA vaccines. In oncology, the Company’s lead asset is Gedeptin®, a gene-directed enzyme prodrug therapy that has completed a multicenter Phase 1/2 trial in advanced head and neck cancers, with a Phase 2 neoadjuvant trial (AdPNP-203) in preparation that will evaluate intra-tumoral Gedeptin with intravenous fludarabine and neoadjuvant pembrolizumab, alongside expanded preclinical work in additional solid tumors. GeoVax is also advancing GEO-MVA, a Mpox and smallpox vaccine candidate that, based on favorable European Medicines Agency advice, is expected to move directly into a single Phase 3 immunobridging trial. Supported by worldwide rights, a growing intellectual property portfolio, and scalable manufacturing plans, including a shift from egg-based to modern cell line platforms, GeoVax is led by an experienced management team focused on high-impact vaccines and immunotherapies for urgent, underserved medical needs.

**Key Points**

- On November 13, 2025, GeoVax reported a Q3 2025 net loss of $6.3 million ($0.31 per share) versus $5.8 million ($0.91 per share) in Q3 2024. The Company ended the quarter with $5.0 million in cash. 
- Phase 2 trials of GEO-CM04S1 in immunocompromised and CLL patients continue to show strong T-cell and antibody responses, no serious vaccine-related adverse events, and achievement of the CLL trial’s primary immunogenicity endpoint.
- GEO-MVA advanced along an EMA-endorsed pathway in which a single Phase 3 immunobridging trial is expected to support centralized EU marketing authorization, with WHO’s reaffirmation of Mpox as a global emergency and reinforcing the need for additional MVA-based vaccine supply.
- Gedeptin® is being advanced into AdPNP-203, a Phase 2 neoadjuvant trial in resectable head and neck squamous cell carcinoma (Gedeptin + fludarabine + neoadjuvant pembrolizumab), with preclinical work expanding into triple-negative breast and cutaneous malignancies.
- GeoVax reinforced its role as a U.S.-based “Made-in-America” MVA vaccine developer, highlighting continuous avian cell-line manufacturing, alignment with U.S. biodefense and onshoring priorities, and active engagement with U.S. and global health agencies.
- The Company’s IP portfolio includes a June 2025 U.S. patent on a novel MVA-based malaria vaccine construct and more than 135 patents across 23 families supporting its multi-antigen infectious disease and oncology platform.  
  .

***********************************************

Visit our [Corporate Profile](https://www.crystalra.com/research-library/geovax-0-0) and [Key Points](https://www.crystalra.com/geovax-key-points-0-0)<https://www.crystalra.com/magnegas-key-points>pages

for the latest research on GeoVax Labs, Inc.

***********************************************

 

[View full post](https://www.crystalra.com/blog/november-2025-update-on-geovax-labs-inc.-govx-nasdaq)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Karen Goldfarb"
  },
  "dateModified" : "2025-11-17T17:52:00.732Z",
  "datePublished" : "2025-11-17T17:46:09Z",
  "headline" : "November 2025 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)",
  "image" : {
    "@type" : "ImageObject",
    "height" : 900,
    "url" : "https://150154.fs1.hubspotusercontent-na1.net/hubfs/150154/GeoVax%20Labs%20Update%2011-17-2025-1.png",
    "width" : 1600
  },
  "mainEntityOfPage" : "https://www.crystalra.com/blog/november-2025-update-on-geovax-labs-inc.-govx-nasdaq",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Blog"
  }
}
```